Emerging Novel Combined CAR-T Cell Therapies

Cancers

Anh Nguyen¹  Yihui Shi²  Gary Johanning³ 

[1] College of Graduate Studies, California Northstate University, Elk Grove, CA 95757, USA;College of Medicine, California Northstate University, Elk Grove, CA 95757, USA;SunnyBay Biotech, Fremont, CA 94539, USA;

关键词: chimeric antigen receptor (CAR);    T cell;    immunotherapy;    hematologic malignancies;    solid tumor;    target antigen;   

DOI  :  10.3390/cancers14061403

来源: DOAJ

【 摘 要 】

Chimeric antigen receptors (CAR) T cells are T cells engineered to express membrane receptors with high specificity to recognize specific target antigens presented by cancer cells and are co-stimulated with intracellular signals to increase the T cell response. CAR-T cell therapy is emerging as a novel therapeutic approach to improve T cell specificity that will lead to advances in precision medicine. CAR-T cells have had impressive outcomes in hematological malignancies. However, there continue to be significant limitations of these therapeutic responses in targeting solid malignancies such as heterogeneous antigens in solid tumors, tumor immunosuppressive microenvironment, risk of on-target/off-tumor, infiltrating CAR-T cells, immunosuppressive checkpoint molecules, and cytokines. This review paper summarizes recent approaches and innovations through combination therapies of CAR-T cells and other immunotherapy or small molecule drugs to counter the above disadvantages to potentiate the activity of CAR-T cells.

【 授权许可】

Unknown